US approves AstraZeneca, Daiichi's treatment for lung cancer
FILE PHOTO: The company logo for pharmaceutical company AstraZeneca is displayed on a screen on the floor at the New York Stock Exchange, US, Apr 8, 2019. (Photo: Reuters/Brendan McDermid)
AstraZeneca and its partner Daiichi Sankyo have won approval from US regulators for their precision drug Datroway to treat a type of lung cancer, marking the first approval of the therapy in this indication and expanding access for patients.
Datroway has been approved in the United States, the world's biggest pharmaceuticals market, to treat an advanced form of non-small cell lung cancer in adults who had received prior treatment, AstraZeneca said on Tuesday, adding it was the first such therapy to get the greenlight there for treating lung cancer.
Keep updated, follow The Business Standard's Google news channel
